Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts

被引：32

作者：

van der Helm, L. H. ^{[1
]}

Veeger, N. J. G. M. ^{[1
]}

van Marwijk Kooy, M. ^{[2
]}

Beeker, A. ^{[3
]}

de Weerdt, O. ^{[4
]}

de Groot, M. ^{[5
]}

Alhan, C. ^{[6
]}

Hoogendoorn, M. ^{[7
]}

Laterveer, L. ^{[8
]}

van de Loosdrecht, A. A. ^{[6
]}

Koedam, J. ^{[9
]}

Vellenga, E. ^{[1
]}

Huls, G. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, NL-9713 GZ Groningen, Netherlands

[2] Isala Klin, Dept Internal Med, Zwolle, Netherlands

[3] Spaarne Ziekenhuis, Dept Internal Med, Hoofddorp, Netherlands

[4] St Antonius Hosp, Dept Internal Med, Nieuwegein, Netherlands

[5] Med Spectrum Twente, Dept Internal Med, Enschede, Netherlands

[6] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands

[7] Med Ctr Leeuwarden, Dept Hematol, Leeuwarden, Netherlands

[8] Diaconessenhuis, Dept Internal Med, Meppel, Netherlands

[9] Celgene BV, Utrecht, Netherlands

来源：

LEUKEMIA RESEARCH | 2013年 / 37卷 / 08期

关键词：

Acute myeloid leukemia; Older age; Azacitidine; Bone marrow blast count; Predictors; ACUTE MYELOID-LEUKEMIA; INTERNATIONAL WORKING GROUP; CONVENTIONAL CARE REGIMENS; ELDERLY-PATIENTS; MYELODYSPLASTIC SYNDROMES; RESPONSE CRITERIA; OLDER PATIENTS; PHASE-III; AGE; CLASSIFICATION;

D O I：

10.1016/j.leukres.2013.03.022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-30% bone marrow (BM) blasts, but limited data is available on patients with >= 30% blasts. We analyzed 55 newly diagnosed AML patients, treated with azacitidine. The overall response rate was 42%. Median overall survival (OS) was 12.3 months. We confirmed poor-risk cytogenetics, therapy-related AML, performance score >= 2, and white blood cell count >= 15x10(9)/L as independent adverse predictors for OS. The BM blast percentage, however, had no impact on OS (P=0.55). In conclusion, administration of azacitidine is effective in AML patients with 20-30% and >30% BM blasts. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：877 / 882

页数：6

共 50 条

[31] Impact of FLT3 Mutation Clearance after Front-Line Treatment with Gilteritinib Plus Azacitidine, or Gilteritinib or Azacitidine Alone in Patients with Newly Diagnosed AML: Results from the Phase 2/3 Lacewing Trial
Wang, Eunice S.
Altman, Jessica K.
Minden, Mark D.
Wu, Ruishan
Rich, Elizabeth Shima
Hill, Jason E.
BLOOD, 2021, 138
[32] Efficacy and safety of Azacitidine (Vidaza®) in patients with myelodysplastic Syndromes (MDS, Int-2 or high risk), AML (WHO 20-30% Blasts), or CMMoL (10-29% bone marrow blasts without myeloproliferative disorder): First interim analysis of the non-interventional study "PIAZA"
Wehmeyer, J.
Zaiss, M.
Losem, C.
Schmitz, S.
Teichmann, B.
Harde, J.
Hasskarl, J.
ONKOLOGIE, 2013, 36 : 241 - 241
[33] Diffuse Pattern of Bone Marrow Involvement in MRI Is Associated with High Risk Cytogenetics and Poor Outcome in Newly Diagnosed, Symptomatic Patients with Multiple Myeloma
Moulopoulos, Lia A.
Kastritis, Efstathios
Terpos, Evangelos
Gkotzamanidou, Maria
Roussou, Maria
Koureas, Andreas
Migkou, Magdalini
Gavriatopoulou, Maria
Gika, Dimitra
Koutoulidis, Vasilios
Dimopoulos, Meletios Athanasios
BLOOD, 2011, 118 (21) : 1676 - 1677
[34] AZACITIDINE IMPROVES SURVIVAL IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES WITH 20-30% BONE MARROW BLASTS AND POOR-RISK CYTOGENETIC CATEGOR
Falantes, J. F.
Calderon, C.
Marquez-Malaver, F. J.
Carrillo, E.
Bernal, R.
Morales, R.
Parody, R.
Gonzalez, J.
Montero, I.
Martino, M. L.
Espigado, I.
Perez-Simon, J. A.
HAEMATOLOGICA, 2014, 99 : 614 - 614
[35] RESULTS OF BONE MARROW EXAMINATIONS IN PATIENTS WITH CHRONIC IDIOPATHIC (IMMUNE) THROMBOCYTOPENIC PURPURA TREATED WITH ELTROMBOPAG FOR MORE THAN ONE YEAR
Bussel, J.
Saleh, M.
Meyer, O.
Frederiksen, H.
Johnni, D.
Aivado, M.
Brainsky, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 253 - 254
[36] RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
Dombret, H.
Seymour, J. F.
Butrym, A.
Wierzbowska, A.
Selleslag, D.
Jang, J. H.
Kumar, R.
Cavenagh, J.
Schuh, A.
Candoni, A.
Recher, C.
Sandhu, I.
Bernal, T.
Al-Ali, H. K.
Martinelli, G.
Stone, R. M.
Minden, M. D.
McIntyre, H.
Songer, S.
Lucy, L.
Beach, C.
Doehner, H.
HAEMATOLOGICA, 2014, 99 : 788 - 789
[37] SURVIVAL OUTCOME IN PATIENTS TREATED IN 2ND OR MORE COMPLETE REMISSION WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION - A COMPARISON BETWEEN ALL AND AML
AGER, S
MARCUS, RE
BROADBENT, V
EXPERIMENTAL HEMATOLOGY, 1993, 21 (08) : 1063 - 1063
[38] Retrospective comparison of reduced-intensity conditioning and conventional myeloablative conditioning for allogeneic haematopoietic stem cell transplantation using HLA identical sibling donors in AML and MDS with less than 10% bone marrow blasts
Martino, R.
Van Biezen, A.
de Wreede, L.
Fiocco, M.
von dem Borne, P.
Robin, M.
Volin, L.
Bornhaeuser, M.
De Witte, T.
Rocha, V.
Kroeger, N.
Mohty, M.
BONE MARROW TRANSPLANTATION, 2012, 47 : S34 - S35
[39] Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
DiNardo, Courtney D.
Stein, Anthony S.
Fathi, Amir T.
Montesinos, Pau
Odenike, Olatoyosi
Kantarjian, Hagop M.
Stone, Richard M.
Koralek, Daniel O.
Van Oostendorp, Jason
Gong, Jing
Gupta, Ira
Vyas, Paresh
BLOOD, 2017, 130
[40] RESPONSE-ADAPTED AZACITIDINE AND INDUCTION CHEMOTHERAPY IN PATIENTS >60 YEARS OLD WITH NEWLY DIAGNOSED AML ELIGIBLE FOR CHEMOTHERAPY: RESULTS OF THE DRKS00004519 STUDY OF THE EAST GERMAN STUDY GROUP
Jaekel, N.
Hubert, K.
Krahl, R.
Haenel, M.
Maschmeyer, G.
Herbst, R.
Jakob, C.
Schulze, S.
Wang, S. -Y.
Cross, M.
Kahl, C.
Wass, M.
Sayer, H.
Brosteanu, O.
Niederwieser, D.
Al-Ali, H. K.
HAEMATOLOGICA, 2017, 102 : 214 - 214

← 1 2 3 4 5 →